Live feed08:05:00·196dPRReleasevia QuantisnowCadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)ByQuantisnow·Wall Street's wire, on your screen.CVKD· Cadrenal Therapeutics Inc.Health Care
